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Guided surgerya b s t r a c t
Optical medical imaging is a rapidly growing area of research and development that offers a multitude of
healthcare solutions both diagnostically and therapeutically. In this review, some of the most recently
described peptide-based optical probes are reviewed with a special emphasis on their in vivo use and
potential application in a clinical setting.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Over last decade, optical medical imaging technologies have
received growing attention as non-invasive methods to allow the
visualization and monitoring of biological processes at a molecular
level, with the potential to monitor patients response to therapy in
real-time.1–5
These techniques make use of fluorescent probes that typically
constitute a recognition moiety that targets a disease biomarker
conjugated to a fluorophore thereby providing a signal at the target
site. Among the myriad of fluorescent probes generated those
based on peptide-based recognition elements are of particular
interest with multiple applications reported within a clinical set-
ting for early disease diagnosis or directing surgery.
Fluorescent peptide probes rely on a labelled-peptidic sequence
that is able to bind selectively or become modified to/by the
molecular target overexpressed at the disease site. Compared to
antibodies, peptides offer a multitude of advantages including
rapid distribution, reduced or absent immunogenicity, ease and
scalability of synthesis and affordable labelling.6 In addition, an
increasing number of novel potential molecular ligands for cancer,
bacterial infections and other pathological targets are peptide-
based and these have begun to be widely employed for disease
imaging in vivo.7 This review will focus on peptide-based optical
imaging agents. Due to the complex regulatory issues, possible tox-icity, tissue localization concerns and the now documented lack of
an enhanced permeability and retention (EPR) effect in humans,116
nanoparticle-based probes have been specifically excluded.
1.1. Applications
In oncology, the identification of tumour boundaries is critical
for appropriate surgical resection and surgery remains one of the
most effective ways to treat cancer,8 with the precise removal of
the tumour, a dominant factor in reducing the frequency of local
disease recurrence alongside improving the subsequent efficacy
of chemotherapy and radiotherapy.9,10 However, during surgery,
it is often challenging for surgeons to confidently distinguish
between malignant and normal tissues based on visual inspection
or palpation. MRI, PET and CT can be employed, but direct use dur-
ing surgery is instrumentally complex (e.g. MRI), or hazardous (e.g.
radioactivity for PET)11,12 and even despite their potential applica-
tion, the molecular resolution of these platforms maybe unable to
identify microscopic tumour deposits.
Intraoperative optical imaging, using fluorescent imaging, is a
relatively novel approach that relies on fluorescent contrast agents,
offering clear advantages such as non-invasive real-time imaging,
at high resolution, in the absence of ionizing radiation and at rea-
sonably low cost.13 Furthermore, these systems have other poten-
tial applications including detection of proximal metastases and
assessment of therapeutic response to treatment.14 Nevertheless,
the use of light presents some issues, such as light scattering and
tissue absorbance limiting the ability to quantify fluorescent sig-
nals and detect targets deeper than a few mm (even with NIR
dyes).15,16 Despite this, optical imaging systems have been shown
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surgery has been used on patients with ovarian cancer using a
folate-fluorescein probe17 and other sensors are undergoing clini-
cal trials as will be described in the next sections.
In the case of microbial infections, direct in situ imaging of bac-
teria and fungi would allow rapid and accurate diagnosis of infec-
tion, improving therapy and facilitating specific antimicrobial
treatment.
Optical medical imaging of inflammation is a major area of
research and clinical development. The pathways of acute inflam-
mation, resolution, repair and regeneration are crying out for
molecular imaging biomarkers to guide therapeutic intervention
and disease stratification.
Thus, several fluorescent probes are available for studying such
biological processes in small animal models, and probes have
begun to be used in human trials with applications for human
diagnosis within a clinical setting.18
Molecular optical imaging is still in its infancy and over the last
few years there have been much progresses in this field in terms of
probe design and device technology to overcomemany of the limit-
ing factors and improvediseasedetection in vivo.19 In support of this,
the range of commercial targeted fluorescent probes has expanded
significantly in the past decade. Several companies provide optical
probes for small animal in vivo imaging (PerkinElmer – ProSense,
MMPSense and BacteriSense. Licor – IR800CW RGD, Vergent
Bioscience – probes for caspases and cathepsin imaging) although
to our knowledge none of them have made the full transition to
licensed clinical use. In this review, we will focus on the most
promising peptide-probe candidates for tumour and bacterial infec-
tion imaging in vivo reported recently. We will discuss the probe
designs andmodes of action that has led someof these probes enter-
ing into clinical trials. We will classify the probes according to their
mechanism of action/emission of light namely affinity and activity
probes while the potential of advances such as fluorescent assisted
robotic surgery will also be mentioned.202. Affinity probes
Peptide based affinity probes typically consist of a peptidic
recognition moiety attached to a fluorescent dye with the peptide
moiety driving binding and accumulation of the fluorescent tag at
the biological target. The dye is usually passive in nature but it can
be ‘‘switched-on” upon binding due to environmental changes.
There are many examples such as the in vivo imaging of nerves
with the probe NP-41, (Ac-SHSNTQTLAKAPEHTGK[Dye]-NH2) that
binds preferentially to peripheral nerve tissue after systemic
administration.21 Investigations in mouse models have shown this
could become a unique tool to facilitate nerve repair surgeries and
an aid to prevent accidental transection.22
Another example is a probe that binds bacteria (Fig. 4), but that
only becomes fluorescent due to the switch-on upon binding.23 In
addition, there are many examples of probes that have an amplifi-
cation effect based on the application of a multi-valent scaffold.24
In this review, we have focused on affinity probes for oncology
applications based on receptor binding (mainly c-Met, cholecys-
tokinin-2 (CCK2), gastrin-releasing peptide receptor (GRPR),a,b,3
integrins, somatostatin and EGFR; and affinity probes for bacterial
detection based on binding ligands (mainly Vancomycin, Ubiqui-
cidin, Apidaecin and Polymyxin).2.1. Affinity probes in cancer detection
2.1.1. c-Met
The over-expression of the transmembrane human growth fac-
tor receptor c-Met is known to be associated with tumour growthPlease cite this article in press as: Staderini M., et al. Bioorg. Med. Chem. (201and correlates with a poor clinical prognosis in many cancer
types.25,26 A high affinity optical probe targeting the human c-
Met protein, EMI-137 (1), consists of a sulfonated Cy5-tagged 26
aminoacid peptide with two disulphide bridges (see Fig. 2). Since
c-MET is expressed in early stage colon cancer lesions, that often
are not readily visible during white-light endoscopic procedures,
a first-in-human pilot study27 demonstrated that molecular imag-
ing with the probe was feasible and safe, and enabled the detection
of early-stage lesions. Fifteen patients at high risk of colorectal
neoplasia were included in the study. Fluorescence colonoscopy
with EMI-137 was able to identify additional polyps that were
not visible with white light. EMI-137 (1) is currently in phase IIb
for colorectal cancer (Fig. 1) (NCT2016-002827-27). Other pilot
studies in phase I/II will evaluate the probe and fluorescence imag-
ing to improve the accuracy of surgical excision in patients with
breast cancer or oral cancer (NCT2014-003554-13) and in conjunc-
tion with another optical probe, identify potentially malignant pul-
monary lesions during bronchoscopy (NCT02676050).
2.1.2. Cholecystokinin-2 (CCK2)
The cholecystokinin-2 (CCK2)/gastrin receptor has been identi-
fied as a potential therapeutic and diagnostic target for cancer.
Indeed, it has been well established that this receptor is overex-
pressed in different types of tumours including gastrointestinal,
pancreatic, lung and medullary thyroid cancers.28,29 Furthermore,
it plays an important role in tumourigenesis and cancer progres-
sion.30 The CCK receptor is a G protein-coupled receptor (GPCR)
that upon activation by gastrin or CCK (two peptide hormones)
induces cell proliferation. Interestingly, among the gastrin deriva-
tives, minigastrin (a peptide sequence of 13 amino acids) has been
widely used for radionuclide imaging of CCK2 receptors. Laabs31
replaced the radioactive moiety of minigastrin with a fluorophore
(2, see Fig. 2) for in vivo imaging of cancer in mice. DY-minigastrin
(2) was able to bind to CCK2/gastrin receptors in vitro, and was
suitable for real time imaging of mice with implanted colorectal
carcinoma cells (HT-29) (selectivity was confirmed using the unla-
beled peptide in competitive binding assays).
Following on from the c-Met probe (above) and the highly sul-
fonated Cy5 fluorophore used in EMI-137 (1), Kossatz32 developed
a modified minigastrin probe with a hemicyanine dye (DY-754)
bearing four sulfonate groups and showed that it too had low
unspecific binding to healthy tissues of the gastrointestinal tract.
This probe exhibited a strong affinity and specificity to CCK2 recep-
tors in vitro and the ability of the probe to image tumours in mice
from 2 to 24 h after injection was confirmed with selective distri-
bution in cancer areas confirmed by histological analysis.
2.1.3. Gastrin-releasing peptide receptor (GRPR)
GRPR is overexpressed in prostate, pancreatic, gastric, and small
cell lung cancers. Bombesin (BBN) is a 14-amino acid peptide able
to bind selectively to GRPR and was linked to Alexa Fluor 680 to
generate the affinity probe (AF680-BBN, 3) (Fig. 2) that was tested
on human T-47D breast cancer cells. The probe showed high affin-
ity and specificity to the receptor both in vitro and in vivo.33 AF680-
BBN (3) was used to image lymph nodes and metastasis in prostate
cancers in mice,34 and was able to monitor the spreading of cancer
into the lymph nodes.
2.1.4. aVb3 Integrins
Integrins are a family of cell surface receptors involved in the
attachment of cells to the extracellular matrix. They are heterodi-
meric transmembrane glycoproteins constituted by different sub-
units (a and b).35 The integrin amb3 has been shown to be critical
for tumour regulation and metastasis, playing a pivotal role in
angiogenesis, proliferation and migration of cancer cells. The high
expression of amb3 on endothelial cells during cancer metastasis7), https://doi.org/10.1016/j.bmc.2017.09.039
Fig. 1. Simultaneous white light (WL) and fluorescent light (FL) images of representative lesions of the various morphological and histological subtypes found. (a–c) The
lesions shown are clearly visible in WL and show clearly increased fluorescence. (d) A lesion that, although it is visible in WL, has enhanced visibility in FL. (e, f) Images
representative of the nine lesions that were only visible in FL. Polyps are indicated by the white arrows. Reprinted with permission from Burggraaf et al. Nat Med 21, 955–961
(2015) doi: 10.1038/nm.3641. Copyright  2015, Nature Publishing Group.
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Many optical probes are based on the tripeptide RGD in its linear
or (better) cyclic version as targeting moieties.36 Thus, Huang37
used the dye 800CW coupled to cRGD (800CW-RGD, 4) (Fig. 2) that
was shown to specifically bind to integrin receptors and selectively
accumulate in glioblastoma tissues in vivo in mice allowing fluo-
rescence-guided tumour resection. Building on this approach,
Liu38 generated a similar probe for imaging of tumour vasculature
during tumour angiogenesis. Upon injection in mice bearing pan-
creatic cancer, the probe was able to visualize cancer endothelial
cells over 24 h.
An important point for all probes is the contrast between
tumour and normal tissues. Therefore, multiple efforts have been
made to strengthen the emission signal and reduce the back-
ground. Thus, Choi39 reported a novel optical probe based on cRGD
attached to a zwitterionic fluorophore (ZW800-1) that had a low
nonspecific tissue background. In vivo analysis in mice bearing
human melanoma cells showed that the optical probe had
enhanced signal to non-specific background compared to dyes
such as non-sulfonated (hydrophobic) Cy5.5 and 800-CW. The
specificity of this probe was confirmed by further in vivo experi-
ments in mice with colorectal, breast, pancreatic, and oral tumour
xenografts.40
Multi-valent probes have also been developed based on cRGD.
This includes a cRGD dimer based probe labelled with 800CW that
was investigated in a U87MG tumour model.41 Cai42 conjugated a
fluorophore (ICG-Der-02) to c(RGDyK)2 and used it for in vivo inte-
grin imaging in mice bearing subcutaneous MDA-MB-231 and
U87MG tumours. In this case within 4 h post-injection the probe
accumulated selectively in the cancer tissue and showed good sig-
nal over background.
Cheng43 carried out a comparison study using monomeric,
dimeric and tetrameric Cy5.5 c(RGDyK) in a subcutaneous
U87MG glioblastoma xenograft model. The tetramer provided the
clearest images of the tumour in vivo with the highest contrast
0.5–4 h post-injection. In the light of this, a further probe was
developed by linking a tetrameric RGD peptide to a cyclic decapep-
tide scaffold (RAFT) and labelled with Cy5.44,45 This probe (Cy5-
RAFT-c(RGDfK)4) was successfully used for early detection of deep
ovarian metastases in mice.
Tumour targeting cyclic (RGDyK) peptides have also been used
to functionalize a nanoprobe together with a fluorescent dye (Cy5)
and a blood brain barrier (BBB) permeable peptide (Angiopep-2).
First, the nanoprobe targets and accumulates in the peripheralPlease cite this article in press as: Staderini M., et al. Bioorg. Med. Chem. (201tumour neovasculature, allowing the interaction between the
BBB permeable peptide and a specific receptor on the vascular
endothelial cells. This process facilitates the crossing of the BBB
of the nanoprobe via receptor-mediated transcytosis, enabling
brain tumour detection.46 The G5-PAMAM dendrimer was selected
as platform due to its globular architecture, and the resulting con-
jugated nanoprobe was investigated in mice bearing U87MG
human glioblastoma xenograft cancer. In vivo imaging demon-
strated the ability of the probe to visualize tumours in the brain
with high contrast. In a related study, Li47 developed a probe by
conjugating Cy5.5 to c(RGDfK) on a G5-PAMAM dendrimer via
PEG spacers in order to improve biocompatibility and extend the
blood circulation time. In mice, the probe was able to visualize eso-
phageal adenocarcinoma in vivo (again confirmed histologically).
3. Somatostatin receptor
Overexpression of the somatostatin receptor has been found in
many tumours and radiolabelled somatostatin (SST) derivatives
are commonly used in clinic for the treatment of gastroenteropan-
creatic cancer.48,49 With this in mind, Becker50 developed an opti-
cal probe based on octreotate (a SST analog) labelled with the
fluorescent dye indotricarbocyanine (ITCC) (5, see Fig. 2) that
was investigated for in vivo tumour targeting. Three hours post
injection into mice bearing a RIN38/SSTR2 tumour, fluorescence
was clearly observed in the region of the cancer.
4. Epidermal growth factor receptor (EGFR)
The epidermal growth factor receptor (EGFR) is a cell-surface
receptor overexpressed in many cancer types including glioma.
The ability to non-invasively observe EGFR levels may be of signif-
icant utility in the diagnosis of cancer and monitoring of anticancer
drugs. Two very similar preclinical studies have been published
where the 12-mer peptides, YHWYGYTPQNVI51 (GE-11) or
FPMFNHWEQWPP,52 selected by phage display methods were
labelled with Cy5.5 (GE-11-Cy5.5, 6) (Fig. 2) and applied in vitro
and in vivo in mouse models to detect tumours.
5. Other receptors
There are many other examples, but space precludes full
details. One example is so-called Tumour Paint (BLZ-100) – a7), https://doi.org/10.1016/j.bmc.2017.09.039
Fig. 2. Chemical structures of some representative peptide affinity based probes used for tumour imaging.
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amino-acid peptide, which is able to bind selectively to several
types of cancer cells including glioma, while having negligible tox-
icity in humans. These favorable properties make CTX a promising
scaffold for imaging a broad variety of cancers.53 Thus, a modified
form of CTX was conjugated to indocyanine green to yield BLZ-100,
a fluorescent agent that was extremely efficient at imaging brain
tumours in mouse models.54 After preclinical validation in dogs
with spontaneously occurring solid tumours,55 BLZ-100 was trans-
lated into clinic. It is currently under Phase I clinical trials for treat-
ment of adult skin cancer, sarcoma, pediatric tumours of the CNS,
glioma, and other solid tumours (http://www.clinicaltrials.govPlease cite this article in press as: Staderini M., et al. Bioorg. Med. Chem. (201identifiers: NCT02097875, NCT02464332, NCT02462629,
NCT02234297, NCT02496065).
Another cell-surface receptor of interest as a diagnostic target is
the zinc metalloenzyme prostate-specific membrane antigen
(PSMA) or glutamate carboxypeptidase II. The only FDA approved
imaging agent-targeting PSMA in prostate cancer is ProstaScint, a
radiolabelled antibody. In this context, optical probe design has
tended to relay on the structure of urea based-peptide inhibitors
of PSMA, e.g. the fluorophore 800CW conjugated to a lysine-gluta-
mate urea inhibitor through a spacer of three D-Glu residues to give
PSMA-1-IR800 (7, see Fig. 2).56 The molecule was investigated
in vitro and in vivo proving high binding affinity and selectivity7), https://doi.org/10.1016/j.bmc.2017.09.039
M. Staderini et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxx 5for PSMA on PC3pip tumours, allowing the visualization of the
boundaries of the solid cancer in mouse models and distinguishing
between PSMA-expressing and non-expressing tumours and other
tissues. These data suggest that PSMA targeting molecules have the
potential for clinical applications in intraoperative fluorescence-
guided surgery.
Lysosomal protein transmembrane 4 beta (LAPTM4B) shows
high expression in several solid tumours57 and has been the target
for the generation of a number of peptide-based probes based on
an environmental ‘‘switch-on” dye and dual valency58,59 (8, see
Fig. 2). The ability of this probe to target LAPTM4B was evaluated
in vitro using human hepatocelluar carcinoma cells (HepG2) and
in vivo in tumour bearing mouse models. After 1 h it was possible
to clearly identify the edges of the tumour.
In the field of glioma detection, Burden-Gulley et al.60 described
a probe that labels extracellular cleaved fragments of the receptor
PTP (protein tyrosine phosphatase) that accumulates in the tumour
microenvironment, but is not present in normal brain tissue. The
peptide GEGDDFNWEQVNTLTKPTSD (identified using crystallo-
graphic data from the extracellular segment of the receptor), cap-
able of binding to the PTP receptor, was labelled with Cy5 and
the resultant probe was able to label not only the main tumour
mass and cells at the margin, but also cells that had moved away
from the main tumour mass in an intracranial animal model of
glioma. Dispersed cells, detected up to 3.5 mm away from the
tumour provided high-resolution detail of local tumour cell
migration.5.1. Affinity probes to detect bacterial and fungal infection
Some of the most promising probes for imaging bacteria and
fungi in situ are based on antimicrobial peptides with the vast
majority of work carried out on preclinical infection models. How-
ever, the long-term clinical potential for detecting bacteria in vivo
is huge with possible applications such as the analysis of the infec-
tion of prosthetic materials (which are common sites for bacterial
colonisation) to determination of infective aetiology to direct ther-
apy. The indiscriminate and widespread use of antimicrobials fuels
antimicrobial resistance (AMR) and optical medical imaging offers
a scalable approach for various clinical scenarios, to support
antimicrobial stewardship and guide stratified therapy.
The most frequently developed microbial targeting ligands are
peptide-based antibiotics, although other strategies are also being
used for targeting,61,18,62 such as antibodies, lectins (Concanavalin
A), sugars (maltohexaose, glucose, sorbitol),63 small cationic mole-
cules (Zn-dipicolylamine)64 or fluorogenic molecules that are acti-
vated by specific bacterial enzymes such as b-lactamase,
micrococcal nuclease or nitroreductase.65 Antimicrobial peptides
typically share features such as small size, often possessing both
hydrophobic and cationic characteristics, with net positive charges
created by basic residues such as Lys/Arg/DAPA (2,3-diaminopropi-
onic acid)/DABA (2,4-diaminobutyric acid). Typically their antimi-
crobial activity is dependent upon initial interactions of the
cationic domains of the peptide with the negatively phosphates
groups within the cell membrane of the microorganism.66 Several
reviews have recently addressed the general field of bacteria-tar-
geted probes and the different imaging modalities,61,18,62 therefore
here we will focus only on peptide-based optical imaging probes
(Fig. 3).6. Vancomycin-based probes
Vancomycin is a glycopeptide antibiotic that exhibits potent
activity against Gram-positive bacteria, the most prominent cause
of soft tissue infection and biomaterial-associated infections.Please cite this article in press as: Staderini M., et al. Bioorg. Med. Chem. (201Detection of Gram-positive bacterial infection using vanco-
800CW67 (9, see Fig. 3) has been demonstrated in vivo in a mouse
myositis model, and in an ex vivo human post-mortem contami-
nated implant where it detected early-stage biofilm formation. A
drawback is limited tissue penetration for deeper infections (for
example in hip prosthesis), but it allowed imaging in a mouse
model. This is a promising optical imaging agent due to the exten-
sive use of vancomycin in the clinic and the associate dye
(IRDye800CW), which is being used, in several clinical trials
(https://www.licor.com/clinical_translation/registered_clini-
cal_trials.html), but conjugation to vancomycinwill always be chal-
lenging due to the two available amino groups. Yang et al.68
reported that Cy5.5-labelled vancomycinwas able to bindMycobac-
terium tuberculosis, however only in vitro results were reported.
Vancomycin has also been linked to a self-assembling peptide
(which forms nano-aggregates) and labelled with Rhodamine and
iodine-125 allowing effective imaging of MRSA in muscle and lung
infected murine models,69 although the advantages of forming
nano-aggregates in an imaging scenario are unclear due to the
potential for inherent fluorophore quenching upon aggregation.
Substantial efforts are being made to target vancomycin-resis-
tant bacteria. This includes the preparation of dimers of van-
comycin linked by photosensitizers. With the aid of light,
photosensitizers are able to generate ROS and cause irreversible
damage to the bacteria. Based on this principle, Xing et al.70 con-
structed an adduct with a porphyrin bridging moiety as a photo-
sensitizer meanwhile Feng et al.71 took advantage of the
Aggregation-Induced Emission properties (AIE) of tetrapheny-
lethene to achieve turn on fluorescence upon binding to Gram-pos-
itive bacteria. The resulting probes act as fluorescent agents to
monitor bacteria with photodynamic antimicrobial activity.7. Ubiquicidin-based probes
Ubiquicidin (UBI) is a well-studied antimicrobial peptide (AMP).
This cationic 59-aminoacid peptide displayed high accumulation in
bacterial infections targeting the negatively charged membranes of
Gram-positive and Gram-negative bacteria. The 13-mer fragment
UBI29–41 [TGRAKRRMQYNRR] has been radiolabelled for bacterial
imaging.72 In the field of fluorescent imaging recent examples of
the use of UBI29–41 include the NIR labelled peptide ICG-02-
UBI29–41 (10, see Fig. 3) which was used for bacteria detection in
infected mouse models.73 A dual-modality tracer was generated
by the conjugation of UBI29–41 to a radioisotope and a fluorophore
(111In-DTPA-Cy5-UBI29–41) and was able to detect S. aureus and K.
pneumoniae infections in vivo in mice.74 A more clinically relevant
scenario is offered by bacterially infected human lung tissues.
Thus, UBI29–41 was labelled with the environmentally sensitive flu-
orophore NBD, and subjected to a number of structural modifica-
tions to improve its stability (unmodified it was found to be
rapidly degraded in vivo with the methionine residue a clear point
of concern). A cyclic variant was able to detect bacteria in ex vivo
human lung tissue using fibre-based fluorescence microscopy
(Fig. 4).238. Apidaecin-based probes
Apidaecein-peptides75 are a family of small peptides (18- to 20-
residues, rich in proline) produced by insects and predominantly
active against Gram-negative bacteria while non-toxic to animal
or human cells. Dosselli et al.76 attached a photosensitizer (11,
see Fig. 3) to apidaecein which thus offers a method for improving
both the water solubility of the photosensitizer. Although the por-
phyrins used by Dosselli were poorly fluorescent for imaging they
allowed PDT.7), https://doi.org/10.1016/j.bmc.2017.09.039
Fig. 3. Structure of some of the antimicrobial peptides used to prepare optical imaging probes to detect bacteria and fungi.
6 M. Staderini et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxx9. Polymyxin-based probes
An optical imaging probe have been developed based on the
antimicrobial peptide polymyxin conjugated to the environmen-
tally sensitive fluorophore NBD (12, Fig. 3) with the first in-human
clinical trials of bacteria-targeted optical imaging now in progress
(NCT02491164). This probe aims to label Gram-negative bacteria
in vivo in situ within the distal lung in the intensive care unit.
10. Probes for fungal infection
Although many studies have been carried out with imaging
modalities such as PET77 (e.g. FDG which cannot differentiate
between fungal infections, bacterial infections, malignancy, or
inflammatory lesions) the field of fungal optical imaging is very
unexplored.
A recent example of optical imaging probes for Aspergillus fumi-
gatus,78 the pathogen that causes the fatal disease Invasive Pul-
monary Aspergillosis was recently reported. Here the authors
used Trp-BODIPY in a cyclized version of the antimicrobial
hexapeptide Peptide Antifungal 26 (PAF26, 13, Fig. 3).
10.1. Affinity probes to detect inflammation
Affinity probes developed for fluorescence imaging of neu-
trophils have used the neutrophil-binding peptide cinnamoyl-FPlease cite this article in press as: Staderini M., et al. Bioorg. Med. Chem. (201(D)LF(D)LF (a FPR1 antagonist) targeting the formyl peptide recep-
tor expressed on neutrophils, attached to some form of Cy7. As this
hexapeptide is highly hydrophobic a PEG moiety was used to
enhance its water solubility with results achieved in a mouse
model of ear inflammation.79,80
10.2. Activity based probes
Peptide-based activity probes have long been used to analyse a
variety of enzymes, with the affinity probe endowed with a recog-
nition moiety (i.e. a peptidic sequence that targets a specific enzy-
matic activity overexpressed in a pathological process), a reactive
war-head (that binds to the targeted protein – historically this
used to be a potent alkylating agent, but more subtle variants are
now used) and a reporter group (here a fluorophore). The majority
of activatable peptide-based probes have targeted proteases and
most classes of proteases have been explored (Fig. 5A). Some of
the most recent probes used for in vivo imaging are described
below listed by their target enzyme/class.
In the case of the probes based on Activatable Cell-Penetrating
Peptides82 (ACPPs) (Fig. 5B), probe activation and cargo uptake
require proteolysis of a peptide linker sequence that connects anio-
nic and cationic domains – cleavage then allowing the cationic
domain to enter cells. This method provides detection of spatially
localized enzymatic activity in living tissues through the accumu-
lation of cleaved probe, targeting the cargos to sites of protease7), https://doi.org/10.1016/j.bmc.2017.09.039
Fig. 4. UBI-10 can be used to image bacteria in ex vivo human lung tissue by fibered confocal fluorescence microscopy (FCFM). FCFM imaging of bacteria in suspension (upper
panels) or when co-incubated with ex vivo human lung tissue (lower panels). Left images demonstrate no intrinsic autofluorescence of bacteria. Right panels demonstrate
UBI-10 can image bacteria by FCFM in the presence of ex vivo human lung with a characteristic small round, punctate fluorescence. Adapted from Akram AR, Avlonitis N,
Lilienkampf A, et al. Chem Sci, 2015, 6, 6971–6979. Published by The Royal Society of Chemistry.
M. Staderini et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxx 7activity in vivo. A related strategy is to retain the cleaved substrate
by locating the fluorophore on a peptide bearing amino groups
produced upon cleavage of the probe.83
Quenched Activity Based Probes81 are small molecules that
become covalently bound to a target enzyme in an activity-depen-
dent manner and have a long history in biochemistry.84–86 These
probes typically have a short peptide sequence that is targeted
by the protease, an electrophilic moiety that facilitates binding to
the active site and a fluorophore and quencher. Protease activation
leads to fluorescent protein labelling with release of the quencher
(Fig. 5C). An alternative strategy is to retain the cleaved substrate
by locating the fluorophore in a peptide bearing amino groups pro-
duced upon cleavage of the probe. Ofori et al.83 reported an exam-
ple of this kind of probe (Fig. 6) that was successfully used for
imaging of breast cancer in mouse models.10.3. Cathepsins
Cathepsins are a family of lysosomal cysteine proteases encom-
passing some eleven different members. Numerous studies have
indicated that they play a key role in the degradation of the extra-
cellular matrix (ECM) promoting angiogenesis and tumour pro-
gression. Cathepsins have been reported to have increased
expression in cancer cells and altered localization in the ECM dur-
ing metastasis.87 Bogyo has led this area by the development of a
number of fluorescent (Cy5) activity probes (Fig. 5C).88 It is impor-
tant to remark that the main advantages of the covalent labelling
are the increased durability of the signal and the localization of
the proteolytic activity site. An example of such a probe89 is
BMV-109 (see Fig. 7) based on the surprisingly short peptide recog-
nition sequence (Phe-Lys) coupled with a tetrafluoro phe-
noxymethyl ketone (PKM). This probe gave good target labelling
and showed in vivo stability and was used in murine studies for
noninvasive optical imaging to visualize the shape of breast and
colon tumours with impressive contrast at 1 h post-injection.90
BMV-109 was able to label tissues when administered topicallyPlease cite this article in press as: Staderini M., et al. Bioorg. Med. Chem. (201providing support for further development as a tool for fluores-
cence-guided cancer surgery.
However the covalent labelling strategy has a drawback,
namely stoichiometric labelling (which can be quite weak) with
no possibility of amplifying the signal. Thus, probes have been gen-
erated that undergo turnover, thereby generating an amplified flu-
orescent signal with signal retention within the cleavage site
achieved by a variety of strategies. This includes a protease-acti-
vated fluorescent probe (LUM015) based on a long PEG spacer
(MW = 22 kDa) that remained attached to the fluorophore Cy5
upon enzymatic cleavage thus limiting its diffusion.91 LUM015
was first tested in mice bearing soft tissue sarcoma and breast can-
cer and provided good contrast between tumour and normal tis-
sues, while preclinical toxicity studies of the probe in rats and
dogs revealed no adverse effects. Furthermore, histological experi-
ments indicated the ability of the probe to selectively label canine
tumour tissue. In the light of these findings, LUM015 was trans-
lated to humans and it is currently in Phase 1 clinical trials. In fif-
teen patients with soft tissue sarcoma and breast cancer, the probe
was well tolerated and subsequent fluorescent imaging of human
tissue samples displayed selective distribution of the probe to
tumours with high contrast compared to normal tissue.92
Nevertheless, the use of such a large probe could lead to a slow
uptake into tumours together with unwanted background signals
coming from other tissues, while the peptide sequence could be
prone to activation by other proteases.
A further approach concerning probe design consists of the
introduction of caged fluorophores that become fluorescent upon
enzymatic decaging. As an example the probe Z-Phe-Arg-HMRG
targeting cathepsin was prepared (Fig. 8A).93,94 Enzymatic cleavage
produced an intense fluorescent signal with the probe showing a
200 fold increase in fluorescence upon cleavage. This small turn-
on probe turned out to be able to rapidly image tumour nodules
in a mouse model with a high signal to background ratio. In addi-
tion, local spraying of the probe allowed the visualization of the
tumour margins by fluorescence endoscopy in vivo proving its
potential in clinical applications.7), https://doi.org/10.1016/j.bmc.2017.09.039
Fig. 5. Generic representation of the activation mechanisms of protease-based probes: A) Fluorescence is quenched by a FRET mechanism and it is restored following
enzymatic cleavage. B) Hydrolysis of a ‘‘caged” cell delivery peptides that drives the transport of a fluorophore into cells following activation. C) Quenched Activity Based
Probes81 bind to a target enzyme, with catalysis promoting the loss of the quencher and formation of a fluorescent probe-enzyme complex.
Fig. 6. The fluorophore is attached on the C-terminal side of the cleavable amide
bond, whereas the quenching group is attached to the lysine side chain. Upon
enzymatic cleavage of the substrate, a fluorescent fragment accumulates in
lysosomes due to protonation of the free amine that is produced by the proteolytic
process.
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In an effort to generate an optical probe selective to caspases
which are signature enzymes of apoptosis, Bogyo and co-workers
exploited the same strategy for cathepsins that makes use of irre-
versible inhibitors. AB50-Cy5 had an electrophilic fragment (an
acyloxymethyl ketone) containing the peptidic sequence Glu-Pro-
Asp labelled with Cy5.95 Although cross-reactivity with legumain
was observed, the probe enabled in vivo imaging of the kinetics of
apoptosis in different mouse models by labelling caspase 3 and 7.
Shi et al.96 generated a fluorescent ‘‘light-up” probe by exploit-
ing the aggregation-induced emission (AIE) of tetraphenylethene
(TPE). Thus, they conjugated the peptidic sequence DEVD (general
sequence susceptible to caspase cleavage) to the dye creating a
water-soluble and poorly fluorescent adduct Ac-DEVD-PyTPE
(Fig. 8B). Upon caspase cleavage a strong fluorescence was
observed because of the aggregation of the hydrophobic TPE resi-
dues, however there must always be concerns about probes that
induce aggregation with respect to human imaging.
A further strategy for a turn-on optical probe to image apoptosis
was reported byYe et al.97 In this case the probe endowedwith aNIR7), https://doi.org/10.1016/j.bmc.2017.09.039
Fig. 7. Cathepsins can activate and then covalently bind BMV-109 promoting the loss of the quencher and formation of a fluorescent probe-enzyme complex.
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disulphide moiety that under the reducing tumour microenviron-
ment and caspase cleavage activity underwent an intramolecular
condensation to form a cyclic compound in situ (Fig. 8C). The latter
self-assembled intofluorescent aggregates allowing real-time imag-
ing of tumour cell death in vivo. It is important to remark that the
bio-orthogonal reaction that leads to the formation of the assembled
nanoparticles occurred intracellularly, although the level of fluo-
rophore self-quenching in aggregates might be a concern. That is
important for their retention in apoptotic cells, improved specificity
and signal-to-noise in cancer imaging. Studies inHeLa tumour-bear-
ing mice with doxorubicin treatment showed that the probe was
able to non-invasively image apoptosis providing information about
tumour response over the course of chemotherapy.
10.5. Matrix metalloproteinases (MMPs)
MMPs are one of the most widely studied enzyme families due
to their relationship with cancer and inflammation. MMPs are a
group of zinc containing endopeptidases known to degrade ECM
proteins such as collagens, gelatins, fibronectin, and laminin.
MMP activity is involved in many disease-related processes includ-
ing cancer progression, invasion and metastasis, rheumatoid
arthritis, pulmonary diseases and cardiovascular diseases. SincePlease cite this article in press as: Staderini M., et al. Bioorg. Med. Chem. (201the first description of ACPPs targeting MMPs,82 much progress
has been made using these probes to visualize tumour margins
during surgery98 as proved recently by Orosco et al.99 for detection
of residual microscopic cancer foci (1.2 mm in size) or to detect
metastases with increased sensitivity and specificity.100 MMPs
have also been imaged by the hydrophobic membrane anchoring
of a FRET probe (synthesized using two fluorophores) in cells
derived from a murine bronchoalveolar lavage, although specificity
to MMP-12 needs to be evaluated.101
Probe design in this area has evolved in differentways. For exam-
ple the probe described by Li102 for the detection ofMMP-2 and cas-
pase-3 consisted of a central fluorophore (FAM) attached to two
peptidic substrates for each enzyme both ending with a quencher
unit (Dabcyl) with sequential detection (rather than simultaneous),
and relying on a single fluorophore. Other recent advances include
the targeting of two biomarkers producing probes with dual func-
tionality, such as an activity-based probe that has both detection
(FRET) and affinity (binding) components to improve the accumula-
tion in the target site. One example of this strategy is the probe that
combines a cleavable MMP peptide and cRGD peptide targeting
MMP-2 and integrin avb3 simultaneously.103
Commercially available probes MMPSenseTM (PerkinElmer)
containing the sequence –PLGVR– have been extensively used in
animal studies. Recent examples include MMPSense680TM for7), https://doi.org/10.1016/j.bmc.2017.09.039
Fig. 9. Imaging and PDT with an ACPP probe for MMP-2. Once the ACPP-PpIX
conjugates get into the tumour tissue, activation by extracellular MMP-2 leads to
internalization. Reprinted with permission from Li S-Y, Cheng H, Qiu W-X, et al. ACS
Appl Mater Interfaces 2015, 7, 28319–28329. Copyright 2015 American Chemical
Society.
Fig. 8. A) The enzymatic cleavage of Z-Phe-Arg-HMRG ‘‘decages” the modified rhodamine dye to produce an intense fluorescent signal. B) The probe Ac-DEVD-PyTPE. C)
Cleavage by caspase induces an intramolecular cyclization of C-SNAF that self-assembles into aggregates.
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into cellular composition and real-time dynamics of the stromal
microenvironment.104 Also Chi et al.105 recently reported the use
of MMPSense750TM to facilitate the detection and removal of breast
cancer tumours. The selectivity of these probes to specific MMPs,
or for example to common proteases such as plasmin is a question.
Combined probes for diagnostic and photodynamic (PDT) treat-
ment is an emergent field. For instance an MMP-2 imaging and PDT
probe106 (Fig. 9) which after tail vein injection accumulates at
MMP-2-overexpressing tumour sites. This consisted of an ACPP
with the sequence R9GPLGLAGE8 and a protoporphyrin which
under irradiation (singlet oxygen generation) showed in vivo inhi-
bition of tumour growth.
Currently there is an ongoing phase-1 clinical trial
(NCT02604862) with a peptide-based MMP probe107 that images
intrapulmonary MMP activity in patients.
10.6. Human neutrophil elastase (HNE)
HNE is a serine protease secreted by neutrophils under physio-
logical conditions but when uncontrolled is also involved in thePlease cite this article in press as: Staderini M., et al. Bioorg. Med. Chem. (2017), https://doi.org/10.1016/j.bmc.2017.09.039
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reasons monitoring its activity is therapeutically important. Gehrig
et al.108 described two FRET peptides based on methoxycoumarin/-
coumarin343 or coumarin343/TAMRA and cleavable sequences
QPMAV"VQSVPX (X = Q or EE) respectively for the soluble enzyme
or for insertion in the plasma membrane, and applied them in a
mouse model with acute neutrophilic lung inflammation. Avlonitis
et al.24 developed internally quenched multi-branched (three or
six) scaffolds containing the peptide APEEIMXRQ (X = D or R).
After successfully completing a phase 0/1 study,109 a multi-
branched probe is currently undergoing 2 studies in the setting
of Adult Respiratory Distress Syndrome in the Intensive Care Unit
(NCT02804854). The study involves the delivery of microdoses of
a Neutrophil Activatable Probe by intra-pulmonary instillation to
patients in ICU with pulmonary infiltrates and imaging through
probe-based confocal laser endomicroscopy (pCLE) to test the
utility and safety of this probe.
10.7. Legumain
Legumain is a lysosomal cysteine protease associated with a
number of inflammatory diseases and cancer, upregulated in the
majority of solid tumours. A recent approach to image legumain
activity in vivo has been described using a substrate that contains
the peptide EPD, Cy5/QSY21 as a FRET pair and an acyloxymethyl
ketone (see Section 10.4. above).110 This probe was used to image
legumain activity in twomurine models of cancer, with advantages
over the previous strategy based on an epoxide opening
reaction.111
10.8. Thrombin
Thrombin is a key enzyme in blood coagulation and plays an
important role in atherosclerotic disease development. Peptide-
based probes have been described in the last years for live imaging
in plaques using a thrombin sensing ACPP.112–114 The ACPP labelled
with Cy5 and improved ratiometric versions labelled with Cy5/Cy7
provided good results in mice after systemic injection. The ratio-
metric version could detect thrombin activity more quickly and
turned out to be more reliable and selective due to minor changes
in the peptide sequence. Although further studies are needed, in
clinical applications, such as deep vein thrombosis and stroke,
there are quite broad clinical applications, especially as intravascu-
lar endoscopic catheters may in the future enable optical determi-
nation of vulnerable atherosclerotic plaques. Thrombin activity is
also a major contributor to fibroproliferation and optimized throm-
bin substrates with high selectivity and resistance to plasmin
degradation have been also reported for rapid sensing in lung
tissue.115
11. Conclusions and perspectives
The ultimate goal of clinical imaging approaches are to improve
the diagnosis, prognosis and treatment of patients and to provide a
greater understanding of human biology in both health and dis-
ease. Whilst more established imaging modalities such as PET,
MRI, CT and ultrasound have entered routine clinical use, primarily
as structural imaging platforms, the versatility of optical molecular
imaging (OMI) has the potential to have a significant and major
impact on approaches of molecular imaging using peptidic imaging
probes. OMI is now at the leading front of advances in augmenting
image-guided surgery to guide real-time clinical and also in the
future robotic decision making.
The ability to develop targeted and molecularly specific fluores-
cent peptidic probes has driven the progress in optical imaging in
the last two decades along with low cost and safety. The advancesPlease cite this article in press as: Staderini M., et al. Bioorg. Med. Chem. (201in fluorescence imaging technology should now be focused on
overcoming some of its current limitations, such as its narrow tis-
sue penetration and tuning specificity – as too many probes are
activated by by-stander enzymes. In developing OMI as a platform
for observing molecular events in humans in situ, studies need to
show specific and full knock-down with pharmaceutical inhibitors.
The development of novel optical probes is a key element in the
evolution of OMI, and combined with the discovery of novel
biomarkers has the potential to increase clinical applicability in a
broad number of diseases. Regarding peptide-based probes, their
synthesis relies on standard chemistry methods, where building
blocks can be easily modified for special requirements, and conju-
gation with dyes is usually straightforward. In addition, peptides
are smaller, have less immunogenicity, and have faster rates for
in vivo localization than antibodies. All this taken together suggests
that peptides will remain as important features in many imaging
probes in the future. As they become more sophisticated in design
with novel turn-on approaches and targeted strategies, further
applications will follow with ensuing clinical benefit.
Despite the promising results reported with peptide-based
probes in animal models, it remains difficult to predict how fast
dual imaging/PDT probes will enter clinical practice and there
needs to be much less reliance on poor murine models and much
more on diseased human tissues. The implementation of these
theranostic agents still faces several obstacles such as co-develop-
ment of devices and the real in vivo environment is exceptionally
complex, requiring strict control over energy delivery and evidence
of low toxicity. However, PDT has great potential to transform cur-
rent pathways of diagnosis and therapy as advances in instrumen-
tation progress to theranostic approaches and interventional
image-guided therapy.
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